AC
ZBIO

Allstate Corporation’s Zenas BioPharma ZBIO Stock Holding History

Allstate Corporation’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$463K Buy
18,241
+18
+0.1% +$358 ﹤0.01% 1062
2026
Q1 		$356K Buy
+18,223
New +$409K ﹤0.01% 1059

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Allstate Corporation's ZBIO Position: Q2 2026 in Review

Allstate Corporation increased its Zenas BioPharma (ZBIO) stake by 0.1% in Q2 2026, buying an estimated $358 and bringing the position to 18,241 shares worth $463K. The position accounts for ﹤0.01% of the portfolio, ranked #1062.

Allstate Corporation first reported a position in ZBIO in Q1 2026 and has held it in 2 quarters since. 144 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • Allstate Corporation held 18,241 shares of Zenas BioPharma worth $463K as of Q2 2026.
  • Allstate Corporation bought 18 Zenas BioPharma shares in Q2 2026, an estimated $358.
  • Zenas BioPharma made up ﹤0.01% of Allstate Corporation's portfolio in Q2 2026, its #1062 holding.
  • Allstate Corporation first reported a position in Zenas BioPharma in Q1 2026 and has held it in 2 quarters since.
  • 144 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on Allstate Corporation's 13F filing for Q2 2026, filed 13 Aug 2026.